The changing face of hepatitis C in the new era of direct-acting antivirals

Soriano, Vincent; Labarga, Pablo; Fernández-Montero, José Vicente; Benito, José M.; Poveda, Eva; Rallón, Norma; Sanchez, Clara Marijuan; Vispo, Eugenia; Barreiro, Pablo

doi:10.1016/j.antiviral.2012.10.011

Cited by 26 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In comparison to PEG-INF or RBV based treatments, DAAs have been found to have higher cure rates (90–100% viral clearance rates at 12 weeks) and virtually no side-effects [13]. Many consider these new drugs to be curative [14, 15]. …”

Section: Introductionmentioning

confidence: 99%

Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature

Dowsett

Coward

Lorenzetti

et al. 2017

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background and Aims. The lived experience of HCV has not been well documented in the literature. The aim of this systematic review was to understand the experiences of living with Hepatitis C Virus (HCV). Methods. Five databases were searched from inception until January 19, 2015. Studies were included if they focused on adults diagnosed with HCV; reported experience living with HCV; and described original research. Results. 46 studies were included. Studies found that participants had reduced quality of life due to physical symptoms. Due to physical symptoms and discrimination, many participants switched to part-time work or quit their jobs. Many individuals reported negative experiences with the healthcare system; themes of feeling unsupported, not having adequate information, and not feeling involved in decisions were reported. Stigma significantly impacted those living with HCV. Conclusions. Published literature indicates that those with HCV often feel stigmatized and unsupported in their care, relationships, and work environments, while simultaneously coping with physical and psychological symptoms. This synthesis points to areas where greater education, compassion, and patient-centered healthcare could improve the experience of people living with HCV.

show abstract

Section: Introductionmentioning

confidence: 99%

Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature

Dowsett

Coward

Lorenzetti

et al. 2017

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Excess mortality attributable to HCV may not be addressed by interventions to reduce harm from substance abuse, because the infection often persists after injection drug use has stopped. An improved understanding of the contribution of HCV and general organ system injury to higher mortality rates among HIV positive patients with a history IDU who are treated with ART is urgently needed, now that highly effective treatments for HCV infection are available because this data would inform clinical and cost-effectiveness analyses of the benefit of HCV treatment in dual infected patients (14, 15). …”

Section: Introductionmentioning

confidence: 99%

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals

May

Justice

Birnie

et al. 2015

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background HIV-infected individuals with a history of transmission via injection drug use (IDU) have poorer survival than other risk groups. The extent to which higher rates of hepatitis C (HCV) infection in IDU explain survival differences is unclear. Methods Adults who started antiretroviral therapy (ART) between 2000-2009 in 16 European and North American cohorts with >70% complete data on HCV status were followed for 3 years. We estimated unadjusted and adjusted [for age, sex, baseline CD4 count and HIV-1 RNA, AIDS diagnosis prior to ART, and stratified by cohort] mortality hazard ratios (HR) for IDU (versus non-IDU) and for HCV-infected (versus HCV-uninfected). Results Of 32,703 patients 3,374 (10%) were IDU; 4,630 (14%) HCV+; 1,116 (3.4%) died. Mortality was higher in IDU compared with non-IDU (adjusted HR 2.71; 95% CI 2.32,3.16) and in HCV+ compared with HCV− (2.65; 2.31,3.04). The effect of IDU was substantially attenuated (1.57; 1.27,1.94) after adjustment for HCV, while attenuation of the effect of HCV was less substantial (2.04; 1.68,2.47) after adjustment for IDU. Both IDU and HCV were strongly associated with liver-related mortality (10.89; 6.47,18.3 for IDU and 14.0; 8.05,24.5 for HCV) with greater attenuation of the effect of IDU (2.43; 1.24,4.78) than for HCV (7.97; 3.83,16.6). Rates of CNS, respiratory and violent deaths remained elevated in IDU after adjustment for HCV. Conclusions A substantial proportion of the excess mortality in HIV-infected IDU is explained by HCV co-infection. These findings underscore the potential impact on mortality of new treatments for HCV in HIV-infected people.

show abstract

“…Moreover, potential consequences of emergence of resistance-associated variant viruses and the emerging concerns for cross-resistance need to be recognized. 20 For HCV patients in resource-limited regions, barriers to HCV care not only includes high cost of antiviral therapies, but also the lack of medical infrastructure and laboratories, as well as shortage of healthcare workers and diagnostic tools. 21, 22 …”

Section: Chronic Hepatitis C Virus Infectionmentioning

confidence: 99%

Current and Future Burden of Chronic Nonmalignant Liver Disease

Udompap

Kim

2015

Clinical Gastroenterology and Hepatology

117

View full text Add to dashboard Cite

Disease burden is an important indicator of the state of health of a population. It can be measured as the frequency (e.g. incidence and prevalence) of a condition or its effects including: fatal and non-fatal health loss from disease (e.g. disability-adjusted life years (DALYs)) as well as the financial costs (e.g. direct health care costs and indirect health care expenditures related to lost income due to premature death). Accurate disease burden information is essential for policy-making such as prioritization of health interventions and allocation of resources. Chronic Liver Disease (CLD) causes substantial health and economic burden in the US, where nearly two million deaths annually are attributable to CLD. In the recent past, overall mortality rate of CLD has been increasing. Viral hepatitis and alcoholic liver disease are thought to be the most common etiologies of chronic liver diseases. More recently, the prevalence of non-alcoholic steatohepatitis (NAFLD) is rapidly increasing and non-alcoholic steatohepatitis (NASH) has become a leading indication for liver transplantation. In this work, we assemble available data on the burden of CLD in the United States, focusing on non-malignant complications, whereas the impact on mortality and healthcare expenses of hepatocellular carcinoma (HCC), an important consequence of CLD is discussed elsewhere.

show abstract

The changing face of hepatitis C in the new era of direct-acting antivirals

Cited by 26 publications

References 21 publications

Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature

Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals

Current and Future Burden of Chronic Nonmalignant Liver Disease

Contact Info

Product

Resources

About